Eye and ENT Hospital of Fudan University

ZEISS Makes Fifth Appearance at CIIE, Placing Great Effort in Localization Strategy

Retrieved on: 
Sunday, November 6, 2022
Knowledge, Booth, Fudan University, China International Import Expo, Research, Consumer, Growth, Investment, Convention center, Eye, RMB, Multimedia, Eye and ENT Hospital of Fudan University, Institute, Industry, History, National Institute of Metrology Standardization and Industrial Quality, Suzhou Industrial Park, Health technology, CEO, View, Institute of Biophysics, Chinese Academy of Sciences, Acceleration, Myopia, Ophthalmology, ZEISS, National Exhibition and Convention Center (Shanghai), Innovation Hub, Canadian National Exhibition, Development, Solution, Telescopic sight, Renewable energy, Science, Yangtze Delta, Biophysics

During the past two years China has become the world's largest single market for ZEISS.

Key Points: 
  • During the past two years China has become the world's largest single market for ZEISS.
  • As such a localization strategy with the Chinese market at its center is imminent.
  • On November 5 ZEISS hosted a press conference of ZEISS China localization strategy at its booth in CIIE, introducing its plans in China - it will continue to increase its investments, and will thoroughly implement its localization strategy.
  • With the completion of ZEISS Guangzhou Knowledge City manufacturing base, ZEISS will possess a globally-influential industry ecosystem for healthy eyesight.

Zhaoke Ophthalmology Completed Patient Enrollments for the Phase III Clinical Trials of the Myopia Progression Treatment Drug NVK002

Retrieved on: 
Wednesday, August 3, 2022
World, Motherboard, Atropine, Ageing, State Council, Parent, Eye, Safety, Episode I, Sun, Ministry, Director, Company, Fudan University, S. D. Warren Co. v. Maine Board of Environmental Protection, Eye and ENT Hospital of Fudan University, Control, Research, World Health Organization, Technology, US Foods, Growth, List of education ministries, Education, Business, Adolescence, Food, SEHK, CEO, Board, Ophthalmology, Achievement, FDA, Benjamin, National Health Planning and Resources Development Act, Cover My Eyes (Pain and Heaven), Approximation error, Beijing Tongren Hospital, NDA, CIC, The Company, Hospital, Principal, Hong Kong Stock Exchange, Patient, Overalls, Pharmaceutical industry, Vaccine, Medical imaging, Myopia

The primary objective of the China CHAMP and Mini-CHAMP trials is to evaluate the efficacy and safety of NVK002 for the treatment of myopia progression in children and adolescents.

Key Points: 
  • The primary objective of the China CHAMP and Mini-CHAMP trials is to evaluate the efficacy and safety of NVK002 for the treatment of myopia progression in children and adolescents.
  • These early completions of patient recruitment across both trials, gives the company a strong headstart in moving towards its goal to lead the market in launching a myopia progression treatment drug.
  • Following this, a New Drug Application ("NDA") submission to the US Food and Drug Administration (the "FDA") is expected in 2023.
  • Dr. Li Xiaoyi (Benjamin), Chairman of the Board of Directors, Executive Director and CEO of Zhaoke Ophthalmology, said, "The early completion of the patient recruitment of NVK002's Phase III clinical trials marks another huge and exciting milestone for Zhaoke Ophthalmology.